Therapeutic
Areas of
Focus
INSPIRED BY THE FUTURE IN MEDICINE
ONCOLOGY
CAR-T CELL RECEPTORS OFFER NEW OPTIONS
CAR-T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers
The U.S. Food & Drug Administration (FDA) has approved a new way of treating cancer using modified human T-cells which are harvested from patients and modified to actively seek out and destroy malignant cells.
These new gene transfer therapies are pushing forward an entirely novel treatment approach for cancer patients.
This important advancement offers patients an option where few previously existed. While use of the CAR-T products are limited in scope this is nonetheless a historic step forward and demonstrates a potential new era for how we approach treating cancer. For the last few decades cancer patients have been treated with the four standards of care which include: surgery, chemotherapy, radiation and targeted therapies. Now, this new therapy offers an entirely innovative approach.
Dr. Francis Collins, Director of the National Institutes of Health (NIH) described being thrilled at the news of the first CAR-T cell product’s approval and expressed an eagerness to see where the CAR-T therapies will take us next.
This class of treatments are a step forward towards personalized medicine.
PHARMACEUTICAL INSIGHT AND DIRECTION
Providing service to the pharmaceutical industry in exploring new developments, partnerships and licensing opportunities, determining pre-launch strategies and tactics, enabling successful launch and post-launch execution and promotion, moving forward with the technological changes in real-time and planning tomorrow’s success in advance.
EXPERIENCE AND EXPERTISE
With decades of experience in treatment areas and direction based on years of success in driving market share for established brands and new potentials, we provide insights and research-based strategic guidance for clients who are long-established market leaders as well as start ups working on therapies in development with incredible promise.
FROM AIDS/HIV TO WOMEN’S HEALTH
Our team provides direction and support for therapeutic areas including oncology, immunology, diabetes and for most commercialized therapeutic conditions where medical intervention can provide relief of suffering and life-saving treatments for patients around the world.
DIAGNOSTICS AND LABORATORY INSTRUMENTATION
The field of diagnostics is changing quickly, as new alternatives give healthcare providers and decision makers more insight and information for prognostic factoring and treatment decision-making. We explore potentials for technological advancements providing workflow improvement and even assessing point of care (POC) devices in clinic-based care.
DEVICE POTENTIALS AND USABILITY
From device design to usability and experience (UX), we explore the potential for tools and devices ranging from Class I – III, including injection devices and syringes, auto-injectors, surgical instruments and implants. From consumers to surgeons, purchasing departments and device review boards, we interact with all stakeholders in the process.
CONSUMER MEDICAL
The explosion of smart phones and personal tracking devices has brought the quantified self and increased consumer demand and interaction with their responsibilities for self-care. We explore the new options and apps (Digital Medicine, Software as Medical Device/SaMD, Digital Therapeutics/DTx), devices and software that drive new innovation and direction leading to a new world of consumer-centric healthcare.
THE FUTURE OF PERSONALIZED MEDICINE
The future of healthcare is the patient sample of one, where all care is directed in a unique manner to serve the individual patient based on their specific unmet needs and health defects. We are helping clients gain steps forward on an array of technological advancements pushing towards this goal line, inching closer with improved genetic testing, immunotherapy pharmaceuticals and testing for mutations and markers which guide care.
RARE DISEASES
Finding, recruiting and screening appropriate patients is part of our daily workflow but extra efforts are required to ensure that the data collection for rare diseases is valid and useful. Our work supports treatments for patients with conditions such as hemophilia (various forms), von Willebrand Disease (vWD), alpha-1 antitrypsin deficiency, sickle cell disease (SCD), multiple myeloma, amyotrophic lateral sclerosis (ALS), amongst others.
FROM FIRST LINE TO SALVAGE THERAPY IN ONCOLOGY
We focus on progress for clients offering hope for patients, from initial assessment, classification and staging to therapy choices that provide effective treatment. We explore the options from operability and resectability to radiation, medical therapies, to progression, salvage, relapse and recurrence.